Autopsy report · NCT04857840

Randomized Study of Extended Treatment With Firibastat in Treatment-Resistant Hypertension (REFRESH)

“No Efficacy demonstrated inn the QGC001-3QG1 study”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months before it started.
• Ran for about 1 year 5 months before it stopped.
• 419 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Quantum Genomics SA

Sponsor type

Industry

Conditions

Hypertension (HTN)

Interventions

Firibastat (QGC001) Period 1

Participants

419

Sites

2

Countries

Canada, United States

Trials that died the same way

• A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension
  “The pivotal study, BPS-314d-MR-PAH-302 (NCT01908699), failed to demonstrate efficacy.” (56% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.